Welcome - Register - Login - Help/FAQ - 0 items

Search
Enter keywords, a title or
a report id number below.

Advanced


	Select a currency for use throughout the site

Viewing report

Order by Fax
Ask a Question
Printer Friendly
PDF Brochure

Electronic (PDF)
Site License
Enterprisewide

Live Chat Live Help Software for Website

Endothelin A Receptor Antagonist (atrasentan) Fails to Demonstrate an Advantage in the Treatment of Advanced Prostate Cancer

GlobalData, May 2011, Pages: 5


	Description



		Table of Contents


		Enquire before Buying


		Send to a Friend

Endothelin A Receptor Antagonist (atrasentan) Fails to Demonstrate an Advantage in the Treatment of Advanced Prostate Cancer

Summary

This year another endothelin A receptor antagonist failed to demonstrate an advantage for advanced prostate cancer. With the failure of atrasentan in Phase III followed by the failure of two Phase III trials of zibotentan, there is only one trial left which is exploring an endothelin antagonist in the treatment of advanced prostate cancer and the future of that trial is not bright.

The development of endothelin antagonist for prostate cancer treatment is based on the evidence that the endothelin pathway plays an important role in prostate cancer progression. By blocking the endothelin pathway, the endothelin A receptor antagonist may slow tumor growth and the spread of cancer cells.

Scope

- On April 21, 2011, NCI-supported SWOG Phase III trial’s Data and Safety Monitoring Committee (DSMC) finding suggested that the addition of atrasentan to docetaxel and prednisone (standard chemotherapy regimen) demonstrate no additional survival benefit to hormone-refractory prostate cancer (HRPC) patients compared to patients on chemotherapy alone.
- On February 7, 2011, AstraZeneca announced the failure of another endothelin A antagonist, zibotentan. In the Phase III ENTHUSE Study 15, zibotentan was studied as a monotherapy in patients with non-metastatic HRPC and was stopped because the drug did not show a significant improvement in overall survival. Also in September 2010, Phase III ENTHUSE Study 14, evaluating zibotentan as monotherapy in metastatic HRPC, did not show significant improvement of overall survival. AstraZeneca is continuing with Phase III ENTHUSE Study 33, where zibotentan is being studied in combination with standard chemotherapy in a more advanced metastatic CRPC setting.

Reasons to buy

- Impact analysis of Endothelin A Receptor Antagonist (atrasentan) Fails to Demonstrate an Advantage in the Treatment of Advanced Prostate Cancer

For enquiries please call us on:

+353-1-415-1241 (GMT Office Hours)

1-800-526-8630 (US/Canada Toll Free)

1-917-300-0470 (EST Office Hours)